Sidebar
2019 WHO Update of Recommendations on First- and Second-Line Antiretroviral Regimens
Population
First-Line Antiretroviral Regimes
Preferred 1st Line regimen
Alternative 1st Line regimen
Neonates
AZT + 3TC + RAL
AZT + 3TC + NVP
Children
ABC + 3TC + DTG
ABC + 3TC + LPV/r ABC + 3TC + RAL
Adults and adolescents
TDF + 3TC (or FTC) + DTG
TDF + 3TC + EFV 400 mg
Second-Line Antiretroviral Regimes
Preferred 2nd Line regimen
Alternative 2nd Line regimen
Children and Infants
ABC (or AZT) + 3TC + LPV/r
AZT (or ABC) + 3TC + DTG
ABC (or AZT) + 3TC + EFV
AZT (or ABC) + 3TC + DTG
AZT + 3TC + NVP
ABC + 3TC + DTG
Adults and adolescents
TDF + 3TC (or FTC) + DTG
AZT + 3TC + ATV/r (or LPV/r)
TDF + 3TC (or FTC) + EFV (or NVP)
AZT + 3TC + DTG
AZT + 3TC + EFV (or NVP)
TDF + 3TC (or FTC) + DTG
ABC + 3TC + DTG
AZT+ 3TC + LPV/r (or ATV/r)
3TC lamivudine
ABC abacavir
ATV/r atazanavir/ritonavir
AZT zidovudine
DRV/rdarunavir/ritonavir
DTG dolutegravir
EFV efavirenz
FTC emtricitabine
LPV/r lopinavir/ ritonavir
NVP nevirapine
RAL raltegravir
TDF tenofovir disoproxil fumarate
Read more on 2019 WHO update of recommendations on first- and
second-line antiretroviral regimens
here